- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03602521
Reactivity of Patients With Borderline Personality Disorder to an Ecological Interpersonal Stress (ROI)
Reactivity of Patients With Borderline Personality Disorder to an Ecological Interpersonal Stress : Pathophysiology of Suicidal Behaviors Study Model
Use lay language.
According to the World Health Organization 1 death by suicide occurs every 40 seconds, leading suicide prevention to one of the public health priority.
BPD (Borderline Personality Disorder) is a common condition affecting 6% of the population.
This disorder is characterized by unstable emotions, unstable mood, difficulties with relationship and feer of abandonment.
Borderline Personality Disorder is also the psychopathology the most related to suicidal attempts.
Indeed, up to 50% of the patients admitted to hospital after a suicide attempt are diagnosis with a Borderline Personality Disorder
Negative interpersonal events (events occurring between two people) are known as the main stressor that trigger a suicidal attempt.
People with a Borderline Personality Disorder are highly sensitive to it.
Moreover, neuropeptides such as oxytocin (OXT), vasopressin and opioid are known to be involved in the regulation of the emotions, especially those linked to relationship.
The purpose of this study is to improve knowledge in suicidal behaviors.
After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of patients with a BPD will be compared to healthy controls (HC).
Clinical data reflecting how the participant is feeling will be collected as well.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A dysregulation of the neuropeptides (OXT, vasopressin and opioid) could explain the dysregulation of the emotions of people with Borderline Personality Disorder.
Up to this date there is no other study measuring neuropeptides kinetics of patient with Borderline Personality Disorder after an interpersonal stress.
This task of stress is meant to reproduce what people with Borderline Personality Disorder suffer in their everyday life (ecological).
To reach this point, an imaginary interpersonal stress will be asked to be reproduced by the participants.
Neuropeptides concentrations and clinical data (fear, shame, anger, moral pain, compelling needs (suicidal and non-suicidal)) will be collected at different times (pre stress, post stress immediat, 5 minutes post stress,15 minutes post stress and 40 minutes post stress)
As copeptin ( fragment C terminal of the vasopressin) and vasopressin are found in stoichiometric concentration in the plasma as copeptin is more stable than vasopressin, plasma copeptin level will be used to reflect the one of vasopressin.
The hypothesis is that both the neuropeptide variation and clinical data before and after the interpersonal stress will be higher for the patient with Borderline Personality Disorder than healthy controls.
A correlation between clinical assessments and neuropeptides kinetics is expected. This study will help to identify inter-individual and contextual factors impacting neuropeptide's kinetics
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34295
- Hospital Lapeyronie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
No specific inclusion criteria :
- If taking hormonal contraceptive: able to participate between the 3rd and 18th day after taking the contraceptive If not taking hormonal contraceptive: able to participate between the 5th and 12th day after the first day of the last period
- Able to understand the nature, purpose and methodology of the study
- Having signed the informed consent
- To be affiliated to a social security scheme
Specific inclusion criteria
Borderline Personality Disorder(BPD) :
- Clinical diagnosis of BPD using the SCID II (Structured Clinical Interview for DSM-IV-TR Axis II Personality Disorders)
Healthy controls:
- No personal history of psychiatric disorders (Axis I ) defined by the MINI International Neuropsychiatric Interview according to the DSM-5 criteria
Exclusion Criteria:
- Refusal of participation
- Subject protected by law (guardianship)
- Life time diagnosis of schizoaffective disorder or schizophrenia
- Pregnant or breastfeeding women
- Deprived of liberty Subject (by judicial or administrative decision)
- Exclusion period in relation to another protocol
- Having reached the maximum annual amount of allowances of € 4,500
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BPD
Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of patients with a BPD
|
Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment. After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes. To evaluate the stress efficiency, the evaluator will ask 2 questions :
|
Active Comparator: HC
Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of healthy controls (HC) patients .without
any history of psychopathology
|
Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment. After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes. To evaluate the stress efficiency, the evaluator will ask 2 questions :
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Variation of plasma oxytocin concentrations after an interpersonal stress
Time Frame: from pre interpersonal stress to 5 minutes post stress
|
Evaluate and compare the variation of plasma oxytocin concentrations before and after an interpersonal stress of patients with BPDs vs healthy controls between pre stress to 5 minutes post interpersonal stress.
|
from pre interpersonal stress to 5 minutes post stress
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evolution of plasma oxytocin concentrations
Time Frame: from pre stress to 40 minutes post interpersonal stress
|
Evaluate and compare the evolution of plasma oxytocin concentrations before and after an interpersonal stress of patients with BPDs vs healthy controls.
pre stress, post stress immediat, 5 minutes post stress, 15 minutes post stress and 40 minutes post stress.
|
from pre stress to 40 minutes post interpersonal stress
|
Evolution of plasma copeptin concentrations
Time Frame: from pre stress to 40 minutes post interpersonal stress
|
Evaluate and compare the evolution of plasma copeptin concentrations before and after an interpersonal stress of patients with BPDs vs healthy controls.
pre stress, post stress immediat, 5 minutes post stress, 15 minutes post stress and 40 minutes post stress.
|
from pre stress to 40 minutes post interpersonal stress
|
Evolution of plasma β-endorphin concentrations
Time Frame: from pre stress to 40 minutes post interpersonal stress
|
Evaluate and compare the evolution of plasma β-endorphin concentrations before and after an interpersonal stress of patients with BPDs vs healthy controls.
pre stress, post stress immediat, 5 minutes post stress, 15 minutes post stress and 40 minutes post stress.
|
from pre stress to 40 minutes post interpersonal stress
|
self-damaging compelling needs(suicidal) pre stress
Time Frame: pre stress before the interpersonal stress
|
Basal level of self-damaging compelling needs (suicidal) using a numerical scale (0 = I don't want to kill myself ; 10 = Needs to kill myself maximal imaginable ), before an interpersonal stress.
|
pre stress before the interpersonal stress
|
Evolution of clinical variables: self-damaging compelling needs(suicidal)
Time Frame: from pre stress to 40 minutes post interpersonal stress
|
Evolution of the self-damaging compelling needs (suicidal) using a numerical scale (0 = I don't want to kill myself ; 10 = Needs to kill myself maximal imaginable ) post stress immediat, 5 minutes, 15 minutes and 40 minutes after an interpersonal stress of patients with BPDs in comparison to healthy controls.
|
from pre stress to 40 minutes post interpersonal stress
|
Evolution of clinical variables: self-damaging compelling needs(non-suicidal)
Time Frame: from post stress immediat to 40 minutes just after the interpersonal stress
|
Evolution of the self-damaging compelling needs (suicidal) using a numerical scale (0 = I don't want to kill myself ; 10 = Needs to kill myself maximal imaginable ) post stress immediat, 5 minutes, 15 minutes and 40 minutes after an interpersonal stress of patients with BPDs in comparison to healthy controls..
|
from post stress immediat to 40 minutes just after the interpersonal stress
|
Clinical variable: self-damaging compelling needs(non-suicidal)
Time Frame: pre stress before the interpersonal stress
|
Basal level of self-damaging compelling needs (non-suicidal) using a numerical scale (0 = I don't want to hurt myself ; 10 = Needs to hurt myself maximal imaginable), just before an interpersonal stress.
|
pre stress before the interpersonal stress
|
Evolution of self-damaging compelling needs(non-suicidal)
Time Frame: from post stress immediat to 40 minutes just after the interpersonal stress
|
Evolution of the self-damaging compelling needs (non-suicidal) using a numerical scale (0 = I don't want to hurt myself ; 10 = Needs to hurt myself maximal imaginable) post stress immediat, 5 minutes, 15 minutes and 40 minutes after an interpersonal stress, of patients with BPDs in comparison to healthy controls.
|
from post stress immediat to 40 minutes just after the interpersonal stress
|
psychological pain
Time Frame: pre stress just before the interpersonal stress
|
Basal level of psychological pain using a numerical scale (0 =No psychological pain ; 10= Psychological pain maximal imaginable), just before an interpersonal stress.
|
pre stress just before the interpersonal stress
|
Evolution of clinical variables: psychological pain
Time Frame: from post stress immediat to 40 minutes just after the interpersonal stress
|
Evolution of psychological pain using a numerical scale (0 =No psychological pain ; 10= Psychological pain maximal imaginable) post stress immediat, 5 minutes, 15 minutes and 40 minutes after an interpersonal stress, of patients with BPDs in comparison to healthy controls.
|
from post stress immediat to 40 minutes just after the interpersonal stress
|
Clinical variable: state of shame
Time Frame: pre stress just before the interpersonal stress
|
just before the interpersonal stress Description: Basal level of shame using a numerical scale (0 = No shame ; 10 = Shame maximal imaginable), before an interpersonal stress.
|
pre stress just before the interpersonal stress
|
Evolution of clinical variables: state of shame
Time Frame: from post stress immediat to 40 minutes just after the interpersonal stress
|
Evolution of the state of shame using a numerical scale (0 = No shame ; 10 = Shame maximal imaginable), post stress immediat, 5 minutes, 15 minutes and 40 minutes after an interpersonal stress of patients with BPDs in comparison to healthy controls.
|
from post stress immediat to 40 minutes just after the interpersonal stress
|
Clinical variable: state of anger
Time Frame: pre stress just before the interpersonal stress
|
Basal level of anger using a numerical scale (0 = No anger ; 10 = Anger maximal imaginable), before an interpersonal stress.
|
pre stress just before the interpersonal stress
|
Evolution of clinical variables: state of anger
Time Frame: from post stress immediat to 40 minutes just after the interpersonal stress
|
Evolution of the state of anger using a numerical scale(0 = No anger ; 10 = Anger maximal imaginable), post stress immediat, 5 minutes, 15 minutes and 40 minutes after an interpersonal stress of patients with BPDs in comparison to healthy controls
|
from post stress immediat to 40 minutes just after the interpersonal stress
|
Clinical variable: state of fear
Time Frame: pre stress just before the interpersonal stress
|
Basal level of fear using a numerical scale (0 = No fear ; 10 = Fear maximal imaginable), before an interpersonal stress.
|
pre stress just before the interpersonal stress
|
Evolution of clinical variables: state of fear
Time Frame: from post stress immediat to 40 minutes just after the interpersonal stress
|
Evolution of the state of fear using a numerical scale (0 = No fear ; 10 = Fear maximal imaginable) post stress immediat, 5 minutes, 15 minutes and 40 minutes after an interpersonal stress of patients with BPDs in comparison to healthy controls.
|
from post stress immediat to 40 minutes just after the interpersonal stress
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Deborah Ducasse, MD, Urgence psychiatric lapeyonie Hospital Montpellier
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RECHMPL17_0394
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Female
-
Uppsala UniversityMalmö UniversityCompletedFemale Circumcision | Female Genital Mutilation/CuttingSweden
-
Nadezhda Women's Health HospitalMedical diagnostic laboratory ImunoVitaRecruitingFemale InfertilityBulgaria
-
Newlife Fertility CentreRecruitingInfertility | Infertility,Female | Infertility Unexplained | Infertility of Uterine Origin | Infertility; Female, NonimplantationCanada
-
Istituto Clinico HumanitasCompletedFemale Infertility | SustainabilityItaly
-
Isfahan University of Medical SciencesRecruitingInfertility | Thin Endometrium | Infertility FemaleIran, Islamic Republic of
-
Alexandria UniversityCompleted
-
Alexandria UniversityCompletedFemale InfertilityEgypt
-
Istituto Clinico HumanitasIRCCS San RaffaeleCompleted
-
Bharat Serums and Vaccines LimitedActive, not recruitingFemale InfertilityIndia
-
Northwestern UniversityCompletedMalignant Female Reproductive System NeoplasmUnited States
Clinical Trials on Interpersonal stress
-
Florida State UniversityCompleted
-
Children's Hospital of PhiladelphiaNational Institute of Mental Health (NIMH); University of Illinois at Urbana-Champaign and other collaboratorsCompleted
-
New York State Psychiatric InstituteNot yet recruitingDepression | PTSD | Anxiety | Intimate Partner Violence
-
Emory UniversityRecruitingDepression | Alcoholism | Drug AbuseUnited States
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of California, San FranciscoCompletedDepression | Posttraumatic Stress DisorderChina
-
University of IowaNational Institute of Mental Health (NIMH)Completed
-
University of Colorado, DenverAmerican Psychological Association (APA)CompletedPolycystic Ovary Syndrome | Interpersonal PsychotherapyUnited States
-
University of IowaNational Institute of Mental Health (NIMH)Terminated
-
Eunice Kennedy Shriver National Institute of Child...CompletedOverweight | Overweight AdolescentsUnited States